Default content view for Iron

Nutritional Supplement

Iron

Iron is an essential mineral. It is part of hemoglobin, the oxygen-carrying component of the blood. Iron-deficient people tire easily in part because their bodies are starved for oxygen. Iron is also part of myoglobin, which helps muscle cells store oxygen. Without enough iron, adenosine triphosphate (ATP; the fuel the body runs on) cannot be properly synthesized. As a result, some iron-deficient people become fatigued even when their hemoglobin levels are normal (i.e., when they are not anemic).

References

1. Samuels, AJ. Studies in patients with functional menorrhagia: the antimenorrhagic effect of the adequate replication of iron stores. Isr J Med Sci 1965;1:851-3.

2. Taymor ML, Sturgis SH, Yahia C. The etiological role of chronic iron deficiency in production of menorrhagia. JAMA 1964;187:323-7.

3. Samuels, AJ. Studies in patients with functional menorrhagia: the antimenorrhagic effect of the adequate replication of iron stores. Isr J Med Sci 1965;1:851-3.

4. Taymor ML, Sturgis SH, Yahia C. The etiological role of chronic iron deficiency in production of menorrhagia. JAMA 1964;187:323-7.

5. Dietzfelbinger H. Bioavailability of bi- and trivalent oral iron preparations. Investigations of iron absorption by postabsorption serum iron concentrations curves. Arzneimittelforschung 1987;37:107-12 [review].

6. Davidsson L, Kastenmayer P, Szajewska H, et al. Iron bioavailability in infants from an infant cereal fortified with ferric pyrophosphate or ferrous fumarate.Am J Clin Nutr 2000;71:1597-602.

7. Hansen CM. Oral iron supplements. Am Pharm 1994 Mar;NS34:66-71 [review].

8. Simmons WK, Cook JD, Bingham KC, et al. Evaluation of a gastric delivery system for iron supplementation in pregnancy. Am J Clin Nutr 1993;58:622-6.

9. Ricketts CD. Iron bioavailability from controlled-release and conventional iron supplements. J Appl Nutr 1993;45:13-19.

10. Rudinskas L, Paton TW, Walker SE. Poor clinical response to enteric-coated iron preparations. Can Med Assoc J 1989;141:565-6.

11. Walker SE, Paton TW, Cowan DH, et al. Bioavailability of iron in oral ferrous sulfate preparations in healthy volunteers. Can Med Assoc J 1989;141:543-7.

12. Bender-Gotze C. Therapy of juvenile iron deficiency with bivalent iron dragees (Fe2-fumarate, succinate, sulfate). Controlled double-blind study. Fortschr Med 1980;98:590-3 [in German].

13. Hurrell RF, Furniss DE, Burri J, et al. Iron fortification of infant cereals: a proposal for the use of ferrous fumarate or ferrous succinate. Am J Clin Nutr 1989;49:1274-82.

14. Casparis D, Del Carlo P, Branconi F, et al. Effectiveness and tolerability of oral liquid ferrous gluconate in iron-deficiency anemia in pregnancy and in the immediate post-partum period: comparison with other liquid or solid formulations containing bivalent or trivalent iron. Minerva Ginecol 1996;48:511-8 [in Italian].

15. Frykman E, Bystrom M, Jansson U, et al. Side effects of iron supplements in blood donors: superior tolerance of heme iron. J Lab Clin Med 1994;123:561-4.

16. Martinez C, Fox T, Eagles J, Fairweather-Tait S. Evaluation of iron bioavailability in infant weaning foods fortified with haem concentrate. J Pediatr Gastroenterol Nutr 1998;27:419-24.

17. Hertrampf E, Olivares M, Pizarro F, et al. Haemoglobin fortified cereal: a source of available iron to breast-fed infants. Eur J Clin Nutr. 1990;44:793-8.

18. Calvo E, Hertrampf E, de Pablo S, et al. Haemoglobin-fortified cereal: an alternative weaning food with high iron bioavailability. Eur J Clin Nutr 1989;43:237-43 [review].

19. Fox TE, Eagles J, Fairweather-Tait SJ. Bioavailability of iron glycine as a fortificant in infant foods. Am J Clin Nutr 1998;67:664-8.

20. Pineda O, Ashmead HD, Perez JM, Lemus C. Effectiveness of iron amino acid chelate on the treatment of iron deficiency anemia in adolescents. J Appl Nutr 1994;46:2-13.

21. Sullivan JL. Stored iron and ischemic heart disease. Circulation 1992;86:1036 [editorial].

22. Pollitt E. Poverty and child development: relevance of research in developing countries to the United States. Child Dev 1994;65(2 Spec No):283-95.

23. Hurtado EK, Claussen AH, Scott KG. Early childhood anemia and mild or moderate mental retardation. Am J Clin Nutr 1999;69:115-9.

24. Roncagliolo M, Garrido M, Walter T, et al. Evidence of altered central nervous system development in infants with iron deficiency anemia at 6 mo: delayed maturation of auditory brainstem responses. Am J Clin Nutr 1998;68:683-90.

25. Williams J, Wolff A, Daly A, et al. Iron supplemented formula milk related to reduction in psychomotor decline in infants from inner city areas: randomised study. BMJ 1999;318:693-7

26. Morley R, Abbott R, Fairweather-Tait S, et al. Iron fortified follow on formula from 9 to 18 months improves iron status but not development or growth: a randomised trial. Arch Dis Child 1999;81:247-52.

27. Bridge EM, Livingston S, Tietze C. Breath-holding spells: their relationship to syncope, convulsions and other phenomena. J Pediatr 1943;23:539-61.

28. Holowach J, Thurston DL. Breath-holding spells and anemia. N Engl J Med 1963;268:21-3.

29. Bhatia MS, Singhal PK, Dhar NK, et al. Breath holding spells: an analysis of 50 cases. Indian Pediatr 1990;27:1073-9.

30. Colina KF, Abelson HT. Resolution of breath-holding spells with treatment of concomitant anemia. J Pediatr 1995;126:395-7.

31. Daoud AS, Batieha A, al-Sheyyab M, et al. Effectiveness of iron therapy on breath-holding spells. J Pediatr 1997;130:547-50.

32. Mocan H, Yildiran A, Orhan F, Erduran E. Breath holding spells in 91 children and response to treatment with iron. Arch Dis Child 1999;81:261-2.

33. FDA Medical Bulletin, U.S. Government Printing Office, document number 386-942/00002; February 6, 1995.

34. Nightingale SL. Action to prevent accidental iron poisoning in children. JAMA 1997;27:1343.

35. Krezenlok EP, Hoff JV. Accidental iron poisoning. A problem of marketing and labeling. Pediatrics 1979;63:591-6.

36. Morris CC. Pediatric iron poisonings in the United States. South Med J 2000;93:352-8.

37. Mills KC, Curry SC. Acute iron poisoning. Emerg Med Clin N Am 1994;12;397-413.

38. Cutler P. Deferoxamine therapy in high-ferritin diabetes. Diabetes 1989;38:1207-10.

39. Stevens RG, Graubard BI, Micozzi MS, et al. Moderate elevation of body iron level and increased risk of cancer occurrence and death. Int J Cancer 1994;56:364-9.

40. Weinberg ED. Iron withholding: a defense against infection and neoplasia. Am J Physiol 1984;64:65-102.

41. Oh VMS. Iron dextran and systemic lupus erythematosus. Br Med J 1992;305:1000 [letter].

42. Dabbagh AJ, Trenam CW, Morris CJ, Blake DR. Iron in joint inflammation. Ann Rheum Dis 1993;52:67-73.

43. Bartzokis G, Cummings J, Perlman S, et al. Increased basal ganglia iron levels in Huntington disease. Arch Neurol 1999;56:569-74.

44. Salonen JT, Nyyssonen K, Korpela H, et al. High stored iron levels associated with excess risk of myocardial infarction in western Finnish men. Circulation 1992;86:803-11.

45. Kechl S, Willeit J, Egger G, et al. Body iron stores and the risk of carotid atherosclerosis. Circulation 1997;96:3300-7.

46. Tzonou A, Lagiou P, Trichopoulou A, et al. Dietary iron and coronary heart disease risk: a study from Greece. Am J Epidemiol 1998;147:161-6.

47. Danesh J, Appleby P. Coronary heart disease and iron status. Meta-analyses of prospective studies. Circulation 1999;99:852-4.

48. de Valk B, Marx MMJ. Iron, atherosclerosis, and ischemic heart disease. Arch Intern Med 1999;159:1542-8 [review].

49. Klipstein-Grobusch K, Koster JF, Grobbee DE, et al. Serum ferritin and risk of myocardial infarction in the elderly: the Rotterdam Study. Am J Clin Nutr 1999;69:1231-6.

50. Roob JM, Khoschsorur G, Tiran A, et al. Vitamin E attenuates oxidative stress induced by intravenous iron in patients on hemodialysis. J Am Soc Nephrol 2000;11:539-49.

51. Muñoz EC, Rosado JL, Lopez P, et al. Iron and zinc supplementation improves indicators of vitamin A status of Mexican preschoolers. Am J Clin Nutr 2000;71:789-94.

52. Di Bisceglie AM, Bonkovsky HL, Chopra S, et al. Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon: a multicenter, prospective, randomized, controlled trial. Hepatology 2000;32:135-8.

53. Ferrennini E. Insulin resistance, iron, and the liver. Lancet 2000;355:2181-2 [letter].